Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumiracoxib in knee osteoarthritis
NCT00367315Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2003
- Primary completion
- Feb 2004
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of lumiracoxib in osteoarthritis (OA) (4 arms), sponsored by Novartis. Primary endpoints: Overall OA pain intensity in the target knee at 13 weeks, Patient's global assessment of disease activity at 13 weeks and 1 more. Started Sep 2003; status: completed.
02
Drugs
lumiracoxib
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT00367315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00367315.